 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 June 1996 | Volume 124 Issue 11 | Pages 970-979
Objective: To determine whether increasing age is associated with an increased risk for bleeding during warfarin treatment.
Design: Combined retrospective and prospective cohort studies.
Setting: 6 anticoagulation clinics.
Patients: 2376 patients receiving warfarin for various indications.
Measurements: Bleeding events categorized as minor (resulting in no costs or consequences), serious (requiring testing or treatment), life-threatening, or fatal.
Results: 812 first bleeding events (4 fatal, 33 life-threatening, 222 serious, and 553 minor) occurred during 3702 patient-years. Age was inversely related to the mean warfarin dose and dose-adjusted prothrombin time ratio. The unadjusted incidence of minor bleeding complications did not vary according to age group: 18.0 per 100 patient-years for patients younger than 50 years of age, 21.5 for patients 50 to 59 years of age, 24.0 for patients 60 to 69 years of age; 23.5 for patients 70 to 79 years of age, and 16.3 for patients 80 years of age and older. The unadjusted incidence of serious bleeding complications also did not vary according to age group: 9.3 per 100 patient-years for patients younger than 50 years of age, 7.1 for patients 50 to 59 years of age, 6.6 for patients 60 to 69 years of age, 5.1 for patients 70 to 79 years of age, and 4.4 for patients 80 years of age and older. The unadjusted incidence of life-threatening or fatal complications combined was significantly higher among the oldest patients: 0.75 per 100 patient-years for patients younger than 50 years of age, 0.97 for patients 50 to 59 years of age, 1.10 for patients 60 to 69 years of age, 0.68 for patients 70 to 79 years of age, and 3.38 for patients 80 years of age and older. Patients 80 years of age and older had a relative risk of 4.5 (95% CI, 1.3 to 15.6) compared with patients younger than 50 years of age. After adjustment for the intensity of anticoagulation therapy and the deviation in the prothrombin time ratio using Cox and Poisson regression, age was not generally associated with the occurrence of bleeding; relative risk estimates ranged from 0.99 to 1.03 per year of age (lower-bound 95% CI, 0.97 to 1.01; upper-bound 95% CI, 1.00 to 1.09). The single exception was life-threatening and fatal complications in patients 80 years of age or older (relative risk, 4.6 [CI, 1.2 to 18.1]).
Conclusions: Age did not appear to be an important determinant of risk for bleeding in patients receiving warfarin, with the possible exception of age 80 years or older. The intensity of anticoagulation therapy and the deviation in the prothrombin time ratio were much stronger predictors of risk for bleeding.
Author and Article Information
For The National Consortium of Anticoagulation Clinics*
ARTICLE
The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
*For a complete listing of study participants, see the Appendix.
Acknowledgments: The authors thank Frits Rosendaal and Suzanne Cannegieter for their thoughtful comments on the manuscript.
Grant Support: In part by grants IIR 87-063 and IIR 90-036 from the Health Services Research and Development Program of the Department of Veterans Affairs and by unrestricted educational grants from Boehringer-Mannheim, Inc., and Du Pont Pharma.
Requests for Reprints: Stephan D. Fihn, MD, MPH, Northwest Veterans Affairs Health Services Research and Development Field Program152, Veterans Affairs Puget Sound Healthcare System, 1660 South Columbian Way, Seattle, WA 98108.
Current Author Addresses: Drs. Fihn and Martin and Ms. Callahan, Ms. McDonell, and Ms. Henikoff: Northwest Veterans Affairs Health Services Research and Development Field Program152, Veterans Affairs Puget Sound Healthcare System, 1660 South Columbian Way, Seattle, WA 98108.
This article has been cited by other articles:
|
|
 |
|
  G. M. Cooper, J. A. Johnson, T. Y. Langaee, H. Feng, I. B. Stanaway, U. I. Schwarz, M. D. Ritchie, C. M. Stein, D. M. Roden, J. D. Smith, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Blood, August 15, 2008; 112(4): 1022 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Redman, J. Zheng, S. A. Shamsi, J. Huo, E. J. Kelly, R. J.Y. Ho, D. M. Ritchie, and Yuen Yi Hon Variant CYP2C9 Alleles and Warfarin Concentrations in Patients Receiving Low-Dose Versus Average-Dose Warfarin Therapy Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 29 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 E. A. Nutescu ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2281 - 2291. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation Circulation, May 29, 2007; 115(21): 2689 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Holbrook, R. Labiris, C. H. Goldsmith, K. Ota, S. Harb, and R. J. Sebaldt Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial Can. Med. Assoc. J., May 22, 2007; 176(11): 1583 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rash, T. Downes, R. Portner, W. W. Yeo, N. Morgan, and K. S. Channer A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) Age Ageing, March 1, 2007; 36(2): 151 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Johnson, S. Mehta, and J. T. Granton Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J., November 1, 2006; 28(5): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. I. Shireman, J. D. Mahnken, P. A. Howard, T. F. Kresowik, Q. Hou, and E. F. Ellerbeck Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest, November 1, 2006; 130(5): 1390 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-H. Kristoffersen, G. Thue, and S. Sandberg Postanalytical External Quality Assessment of Warfarin Monitoring in Primary Healthcare Clin. Chem., October 1, 2006; 52(10): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nair, B. Sealove, J. L. Halperin, G. Webber, and V. Fuster Anticoagulation in patients with heart failure: who, when, and why? Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E32 - E38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Torn, W. L. E. M. Bollen, F. J. M. van der Meer, E. E. van der Wall, and F. R. Rosendaal Risks of Oral Anticoagulant Therapy With Increasing Age Arch Intern Med, July 11, 2005; 165(13): 1527 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Dunn, J. Wisnivesky, W. Ho, C. Moore, T. McGinn, and H. S. Sacks Perioperative Management of Patients on Oral Anticoagulants: A Decision Analysis Med Decis Making, July 1, 2005; 25(4): 387 - 397. [Abstract] [PDF]
|
|
|
|
|
|
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Greiver When should I stop anticoagulation for atrial fibrillation? Can. Med. Assoc. J., May 24, 2005; 172(11): 1437 - 1437. [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Kim, N. Martin, E. C. Hsia, R. E. Pyeritz, and D. A. Albert Management of Aortic Disease in Marfan Syndrome: A Decision Analysis Arch Intern Med, April 11, 2005; 165(7): 749 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Menzin, L. Boulanger, O. Hauch, M. Friedman, C. B. Marple, G. Wygant, J. S Hurley, S. Pezzella, and S. Kaatz Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy Among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study Ann. Pharmacother., March 1, 2005; 39(3): 446 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. O'Brien and B. F. Gage Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation JAMA, February 9, 2005; 293(6): 699 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D'Andrea, R. L. D'Ambrosio, P. Di Perna, M. Chetta, R. Santacroce, V. Brancaccio, E. Grandone, and M. Margaglione A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood, January 15, 2005; 105(2): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Mahe, A.-S. Grenard, N. Joyeux, C. Caulin, and J.-F. Bergmann Clinical Experience: Management of Oral Anticoagulant in Clinical Practice: A Retrospective Study of 187 Patients J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2004; 59(12): 1339 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Fang, Y. Chang, E. M. Hylek, J. Rosand, S. M. Greenberg, A. S. Go, and D. E. Singer Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation Ann Intern Med, November 16, 2004; 141(10): 745 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kagansky, H. Knobler, E. Rimon, Z. Ozer, and S. Levy Safety of Anticoagulation Therapy in Well-informed Older Patients Arch Intern Med, October 11, 2004; 164(18): 2044 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 429S - 456S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Dager Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 151 - 162. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Vitale, G. Cappabianca, G. Visicchio, C. Fondacone, V. Paradiso, G. Mannatrizio, and L. d. L. T. Schinosa Midterm evaluation of the Sorin Bicarbon heart valve prosthesis: single-center experience Ann. Thorac. Surg., February 1, 2004; 77(2): 527 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Rich The Management of Venous Thromboembolic Disease in Older Adults J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2004; 59(1): M34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-A. Linkins, P. T. Choi, and J. D. Douketis Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 893 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. A. Gadisseur, W. G. M. Breukink-Engbers, F. J. M. van der Meer, A. M. H. van den Besselaar, A. Sturk, and F. R. Rosendaal Comparison of the Quality of Oral Anticoagulant Therapy Through Patient Self-management and Management by Specialized Anticoagulation Clinics in the Netherlands: A Randomized Clinical Trial Arch Intern Med, November 24, 2003; 163(21): 2639 - 2646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wang, J. M. Massaro, D. Levy, R. S. Vasan, P. A. Wolf, R. B. D'Agostino, M. G. Larson, W. B. Kannel, and E. J. Benjamin A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the Community: The Framingham Heart Study JAMA, August 27, 2003; 290(8): 1049 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J.-A. Wilson, P. S. Wells, M. J. Kovacs, G. M. Lewis, J. Martin, E. Burton, and D. R. Anderson Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial Can. Med. Assoc. J., August 19, 2003; 169(4): 293 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Man-Son-Hing and A. Laupacis Anticoagulant-Related Bleeding in Older Persons With Atrial Fibrillation: Physicians' Fears Often Unfounded Arch Intern Med, July 14, 2003; 163(13): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, R. G. Hart, G. A. Wells, P. Petersen, P. J. Koudstaal, A. L. Gullov, B. S. P. Hellemons, B. G. Koefed, and A. Laupacis A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin Arch Intern Med, April 28, 2003; 163(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker, S. Z. Goldhaber, E. Danielson, Y. Rosenberg, C. S. Eby, S. R. Deitcher, M. Cushman, S. Moll, C. M. Kessler, C. G. Elliott, et al. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism N. Engl. J. Med., April 10, 2003; 348(15): 1425 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]
|
|
|
|
|
|
G. A. Banet, A. D. Waterman, P. E. Milligan, S. K. Gatchel, and B. F. Gage Warfarin Dose Reduction vs Watchful Waiting for Mild Elevations in the International Normalized Ratio Chest, February 1, 2003; 123(2): 499 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. E. Deveras and C. M. Kessler Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate Ann Intern Med, December 3, 2002; 137(11): 884 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Higashi, D. L. Veenstra, L. M. Kondo, A. K. Wittkowsky, S. L. Srinouanprachanh, F. M. Farin, and A. E. Rettie Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy JAMA, April 3, 2002; 287(13): 1690 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Man-Son-Hing and A. Laupacis Balancing the Risks of Stroke and Upper Gastrointestinal Tract Bleeding in Older Patients With Atrial Fibrillation Arch Intern Med, March 11, 2002; 162(5): 541 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Bauer, F. R. Rosendaal, and J. A. Heit Hypercoagulability: Too Many Tests, Too Much Conflicting Data Hematology, January 1, 2002; 2002(1): 353 - 368. [Abstract] [Full Text]
|
|
|
|
 |
|
 P J Devereaux, D. R Anderson, M. J Gardner, W. Putnam, G. J Flowerdew, B. F Brownell, S. Nagpal, J. L Cox, and T. Fahey Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study Commentary: Varied preferences reflect the reality of clinical practice BMJ, November 24, 2001; 323(7323): 1218 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology Circulation, October 23, 2001; 104(17): 2118 - 2150. [Full Text] [PDF]
|
|
|
|
|
|
A. Y. H. Leung, H. C. H. Chow, Y. L. Kwong, A. K. W. Lie, A. T. K. Fung, W. H. Chow, A. S. B. Yip, and R. Liang Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients Blood, October 15, 2001; 98(8): 2584 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1231 - 1265. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wehinger, C. Stollberger, T. Langer, B. Schneider, and J. Finsterer Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation Stroke, October 1, 2001; 32(10): 2246 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Bauer The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications Ann Intern Med, September 4, 2001; 135(5): 367 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Evans and L. Kalra Are the Results of Randomized Controlled Trials on Anticoagulation in Patients With Atrial Fibrillation Generalizable to Clinical Practice? Arch Intern Med, June 11, 2001; 161(11): 1443 - 1447. [Abstract] [Full Text] [PDF] |
Article
